JP7773257B2 - ｍｉＲ－１４０を含む医薬組成物及びその製造方法 - Google Patents

ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Info

Publication number
JP7773257B2
JP7773257B2 JP2024512419A JP2024512419A JP7773257B2 JP 7773257 B2 JP7773257 B2 JP 7773257B2 JP 2024512419 A JP2024512419 A JP 2024512419A JP 2024512419 A JP2024512419 A JP 2024512419A JP 7773257 B2 JP7773257 B2 JP 7773257B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
mir
exosomes
chondrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024512419A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023190271A1 (https=
JPWO2023190271A5 (https=
Inventor
博子 矢永
博道 仁科
茄津 矢永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroko Science
Original Assignee
Hiroko Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroko Science filed Critical Hiroko Science
Publication of JPWO2023190271A1 publication Critical patent/JPWO2023190271A1/ja
Publication of JPWO2023190271A5 publication Critical patent/JPWO2023190271A5/ja
Application granted granted Critical
Publication of JP7773257B2 publication Critical patent/JP7773257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024512419A 2022-03-28 2023-03-26 ｍｉＲ－１４０を含む医薬組成物及びその製造方法 Active JP7773257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022051095 2022-03-28
JP2022051095 2022-03-28
PCT/JP2023/012062 WO2023190271A1 (ja) 2022-03-28 2023-03-26 ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Publications (3)

Publication Number Publication Date
JPWO2023190271A1 JPWO2023190271A1 (https=) 2023-10-05
JPWO2023190271A5 JPWO2023190271A5 (https=) 2024-10-01
JP7773257B2 true JP7773257B2 (ja) 2025-11-19

Family

ID=88201695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512419A Active JP7773257B2 (ja) 2022-03-28 2023-03-26 ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Country Status (5)

Country Link
US (1) US20250223561A1 (https=)
EP (1) EP4501338A4 (https=)
JP (1) JP7773257B2 (https=)
CN (1) CN118973591A (https=)
WO (1) WO2023190271A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016076102A1 (ja) 2014-11-14 2016-05-19 株式会社リジェネシスサイエンス 軟骨細胞の無血清培養方法，及び無血清培地
JP2017108650A (ja) 2015-12-15 2017-06-22 国立大学法人名古屋大学 家畜視床下部繁殖中枢由来不死化神経細胞株
JP2020078333A (ja) 2013-07-30 2020-05-28 京都府公立大学法人 角膜内皮細胞マーカー
JP2021502105A (ja) 2017-11-13 2021-01-28 エヴォックス・セラピューティクス・リミテッド タンパク質操作された細胞外小胞
JP2022501034A (ja) 2018-09-19 2022-01-06 イェディテペ・ウニヴェルシテシYeditepe Universitesi 軟骨組織の生成に使用される単離された中隔軟骨エクソソーム

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US9901600B2 (en) 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
US9550977B2 (en) 2011-12-02 2017-01-24 Gunze Limited Method for producing auricular cartilage tissue
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
HK1257561A1 (zh) 2015-11-05 2019-10-25 株式会社Cysay 永生化干细胞及其制作方法
WO2017195268A1 (ja) 2016-05-10 2017-11-16 株式会社アイシーエレクトロニクス ｍｉＲＮＡをマーカーとする歯周炎検査キット、及び検査方法
KR20180092348A (ko) * 2017-02-09 2018-08-20 주식회사 엑소코바이오 연골세포로 분화되고 있는 제대 및 제대혈 유래 줄기세포로부터 분리된 엑소좀을 포함하는 연골세포 분화 유도 또는 연골조직 재생용 조성물
JP6948059B2 (ja) 2017-09-28 2021-10-13 学校法人 川崎学園 ｍｉＲ−１４０−３ｐによる骨芽細胞からのオステオカルシン産生促進
WO2019093308A1 (ja) 2017-11-09 2019-05-16 国立大学法人広島大学 ｍｉＲＮＡを含むがん治療用医薬組成物
KR102123903B1 (ko) * 2018-08-13 2020-06-17 전북대학교산학협력단 분화인자가 함유된 엑소좀 나노 캐리어 조성물 및 이의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020078333A (ja) 2013-07-30 2020-05-28 京都府公立大学法人 角膜内皮細胞マーカー
WO2016076102A1 (ja) 2014-11-14 2016-05-19 株式会社リジェネシスサイエンス 軟骨細胞の無血清培養方法，及び無血清培地
JP2017108650A (ja) 2015-12-15 2017-06-22 国立大学法人名古屋大学 家畜視床下部繁殖中枢由来不死化神経細胞株
JP2021502105A (ja) 2017-11-13 2021-01-28 エヴォックス・セラピューティクス・リミテッド タンパク質操作された細胞外小胞
JP2022501034A (ja) 2018-09-19 2022-01-06 イェディテペ・ウニヴェルシテシYeditepe Universitesi 軟骨組織の生成に使用される単離された中隔軟骨エクソソーム

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Immunology，2012年，Vol.136，pp.192-197
J． Biol. Chem.，2003年，Vol.278, No.22，pp.20083-20090
Osteoarthritis and Cartilage，2011年，Vol.19, Supplement 1, S28，Abstract No.49
Scientific Reports，2016年，Vol.6, Article No.33935，pp.1-11
Stem Cell Research & Therapy，2018年，Vol.9，Article No.318

Also Published As

Publication number Publication date
CN118973591A (zh) 2024-11-15
US20250223561A1 (en) 2025-07-10
JPWO2023190271A1 (https=) 2023-10-05
EP4501338A1 (en) 2025-02-05
WO2023190271A1 (ja) 2023-10-05
EP4501338A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
EP3594348B1 (en) C/ebp alpha short activating rna compositions and methods of use
WO2025054270A1 (en) Compositions and methods for treating cancer
MX2015004641A (es) Modulacion de la expresion del receptor androgenico.
EA005424B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СВЯЗАННОГО С bcl-2 НАРУШЕНИЯ С ИСПОЛЬЗОВАНИЕМ bcl-2-АНТИСМЫСЛОВЫХ ОЛИГОМЕРОВ
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
US20210254069A1 (en) Combination therapies comprising c/ebp alpha sarna
WO2016100858A1 (en) Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
CN117717565A (zh) 反义寡核苷酸在制备治疗食管癌药物中的应用
RU2766356C2 (ru) Кобитолимод для применения при лечении воспалительного заболевания кишечника
US20150272992A1 (en) Treatment of Tumors with Activated Mesenchymal Stem Cells
JP7773257B2 (ja) ｍｉＲ－１４０を含む医薬組成物及びその製造方法
JP2019532635A (ja) 腫瘍溶解性ウイルスを腫瘍に標的化する方法
WO2014180304A1 (zh) J1-001化合物作为抗癌药物的用途
KR20200056794A (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 암 전이 억제용 조성물
US11951178B2 (en) Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
KR20230026096A (ko) 줄기세포 유래 세포외소포체를 유효성분으로 포함하는 조성물
JP2021028297A (ja) マイクロｒｎａ及びその誘導体を有効成分とするがん治療剤
EP4043027A1 (en) Application of peg interferon and proto-oncogene product targeting inhibitor in synergistic treatment of renal carcinoma
US20250302918A1 (en) Methods and compositions relating to treatment of cns diseases
KR102710867B1 (ko) Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
TW202529742A (zh) 組合物、篩選方法及組合物之製造方法
CN115804791A (zh) 间充质干细胞来源的外泌体治疗ilk信号通路相关疾病的方法和药物组合物
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
CN120549959A (zh) 一种靶向RAC1B的siRNA在制备治疗肺癌的药物中的应用
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7773257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150